Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26075226
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Biomed+Res+Int
2015 ; 2015
(ä): 317465
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Advances in anti-IgE therapy
#MMPMID26075226
Yalcin AD
Biomed Res Int
2015[]; 2015
(ä): 317465
PMID26075226
show ga
Omalizumab depletes free IgE in the blood and interstitial space and inhibits IgE
binding to Fc?RI on basophils, mast cells, and dendritic cells. We stopped
omalizumab treatment after four years. Recurrences of urticaria symptoms were
found to be higher in patients with chronic urticaria than recurrences of
asthmatic symptoms in severe persistent asthma patients. For the very first time,
we used omalizumab in symptomatic therapy of recurrent laryngeal oedema and
urticaria attacks in a patient with postoperative pulmonary carcinoid tumor for
eight months. During the four years of follow-up, no recurrence was noted in
pulmonary carcinoid tumor. Control PET CT results revealed normal findings. After
omalizumab treatment, laryngeal oedema and urticaria symptoms were decreased. The
most common adverse reaction from omalizumab is injection site induration,
injection site itching, injection site pain, and bruising but the package insert
contains warnings regarding parasitic infections. While there are no reports of
fatal anaphylaxis as a result of omalizumab, some cases have been serious and
potentially life-threatening. Therefore, the FDA requires that people receiving
omalizumab be monitored in the physician's office for a period of time after
their injections.
free
free
free
